Company: CMND
Filing Date: 2025-12-05
Form Type: F-1/A
Source: 0001213900-25-118772
Chunk: 2

Company: Clearmind Medicine Inc.
Filing Date: 2025-12-05
Form: F-1/A
Chunk 2
---
 prospectus that forms a part of the 2024 Registration Statement, of up to 1,126,480 Common Shares, issuable upon the exercise of the January 2024 PIPE Warrants. In connection with our issuance of convertible promissory notes, or the Promissory Notes, pursuant to securities purchase agreements entered into on September 17, 2025, or the SPAs, with certain institutional investors, or the CLA Investors, the number of Common Shares underlying the January 2024 PIPE Warrants was adjusted in accordance with the terms of the January 2024 PIPE Warrants. As a result of such adjustment, the January 2024 PIPE Warrants are now exercisable for an additional 12,545,230 Common Shares beyond the 1,126,480 Common Shares registered in the 2024 Registration Statement. This prospectus is being filed to register the resale of these additional 12,545,230 Common Shares issuable upon exercise of the January 2024 PIPE Warrants, as a result of the adjustment. The selling shareholders are identified in the table commencing on page 133. We will not receive any proceeds from the sale of the common shares by the selling shareholders. All net proceeds from the sale of the common shares covered by this prospectus will go to the selling shareholders. However, we may receive the proceeds from any exercise of warrants if the selling shareholders do not exercise the warrants on a cashless basis, if and when exercised. See “Use of Proceeds.” The selling shareholders may sell all or a portion of the common shares from time to time in market transactions through any market on which our common shares are then traded, in negotiated transactions or otherwise, and at prices and on terms that will be determined by the then prevailing market price or at negotiated prices directly or through a broker or brokers, who may act as agent or as principal or by a combination of such methods of sale. We will bear all of the expenses incurred in connection with the registration of these shares. The selling shareholders will pay any underwriting discounts and selling commissions and/or similar charges incurred in connection with the sale of the shares. See “Plan of Distribution”. Our Common Shares are currently traded on the Nasdaq Capital Market, or Nasdaq, under the symbol “CMND.” On December 3, 2025, the reported sale price of our Common Shares on the Nasdaq was $0.111. Our Common Shares also trade on the Frankfurt Stock Exchange, or FSE, under the symbol “CW